Brief: Clover Biopharmaceuticals's Unit Enters Collaboration Agreement With Jiangsu Ascentage Pharma
09/12/2021 15:19
Dec 9 (Reuters) - Clover Biopharmaceuticals Ltd 2197.HK :
* UNIT ENTERED INTO A COLLABORATION AGREEMENT WITH JIANGSU
ASCENTAGE PHARMA
* DEAL TO EXPLORE TREATMENT OPTIONS AND ALTERNATIVES TO
SURGERY
FOR PATIENTS SUFFERING FROM PERITONEAL CARCINOMATOSIS
Source text for Eikon: ID:nHKS3LdvCQ
Further company coverage: 2197.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascentage Pharma International
See all newsBrief: Ascentage Pharma Group Says Lisaftoclax Granted Breakthrough Therapy Designation In China
China's Ascentage Pharma climbs as chairman buys shares on market
Brief: Ascentage Pharma Group International's Chairman Buys 38,630 Shares
Brief: Ascentage Pharma Group International Posts H1 Net Loss Attributable RMB816.7 Million
China's Ascentage Pharma H1 revenue rises 29% on Lisaftoclax ramp-up